- Novel flow-through invention offers critical enablement for future system design strategies for groundbreaking biotherapeutics research, as well as drug discovery & development
- Development of next generation Barocycler instruments to allow “hands-free” sample processing that will increase accuracy, reduce costs and avoid contamination
- Global sample preparation market projected to reach $8.2 billion by 2024
- Global proteomics market projected to reach $21.87 billion in 2021
- PBIO’s innovative ultra-shear pressure-based platform technology (UST) being used in federally-funded food safety and preservation development program at Ohio State University
- Potential applications for UST include pharmaceuticals, nutraceuticals, food and beverages, lubricants, paints and cosmetics
Pressure BioSciences Inc. (“PBI”) (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform solutions to the worldwide life sciences industry, has added another patent to its intellectual property portfolio, bringing the total to 21 patents. Issued as U.S. Patent 9995661 and titled “Flow-through High Hydrostatic Pressure Microfluidic Sample Preparation Device and Related Methods Therefor,” this new patent is a significant development in the company’s strategic plan to develop automated “hands-free” sample handling for the next generation of PBI’s high-pressure sample preparation platform systems, a news release states (http://nnw.fm/1gOh3).
The global sample preparation market is projected to reach $8.2 billion by 2024, according to a report by TransparencyMarketResearch (http://nnw.fm/u1I4Y). Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument system, which can be used to exquisitely control the sample preparation process. Based on the company’s patented and enabling pressure cycling technology (PCT) platform, over 300 Barocycler systems have been installed in approximately 200 academic, government, pharmaceutical and biotech research laboratories worldwide. These laboratories use the PCT instrument system for multiple applications, including the preparation of samples for biomarker and target discovery, soil & plant biology, anti-bioterror and forensics studies. There are over 100 independent scientific publications highlighting the advantages of the PCT system in such studies, many from worldwide key opinion leaders.
“This long-anticipated patent is a very important development for the Company on multiple fronts, and the timing of its issuance could not be better,” Dr. Alexander Lazarev, PBI’s vice president of research and development, stated in the release. “This invention also enables a unique capability for maintaining high pressure in a flow-through format (rather than the current batch processing), which we expect will facilitate the development of new, automated continuous process monitoring tools applicable to diverse segments of the life sciences industry.”
The invention’s novel flow-through concept offers critical enablement for future system design strategies for epitope characterization, Lazarev noted. An epitope is the antibody binding site on an antigen capable of eliciting an immune response. “This is an emerging area in development and production of biotherapeutics that could revolutionize personalized therapy for numerous medical conditions, including autoimmune diseases and a variety of rare medical disorders,” Lazarev explained.
PBI’s latest, patented invention will allow for further development of a much sought-after, hands-free, automated workflow, providing valuable enhancements in efficiencies, throughput and contamination avoidance for the company’s instrument and consumable product lines, Richard T. Schumacher, president and CEO of PBI, added.
“We also believe this invention will accelerate our expansion into larger scale applications in multiple major business segments for the Company, particularly in the rapidly growing field of proteomics research,” Schumacher said. “Growth in proteomics and other additional areas should further cement and expand market acceptance and recognition for PBI’s innovative and enabling pressure-based platform technologies and spur concomitant growth in revenue and shareholder value.”
According to a market report by Research and Markets, the worldwide biopharmaceuticals market in 2014 reached a valuation of $160.44 billion.
Pressure BioSciences is forecast to grow at a compound annual growth rate (CAGR) of 76 percent in the next five fiscal years from 2018 to 2022, according to a Zacks Research Report issued on July 26, 2018 (http://nnw.fm/F3GhM). In the Zacks Small-Cap Research Report, the company’s fair value for PBIO shares was raised to $12/share from a previous $10/share. Zacks’ optimism regarding Pressure BioSciences is tied to a number of recent achievements and collaborative research programs, expansion of the company’s sales and marketing capabilities and a newly established multinational co-marketing partner, ISS Inc.
The future looks bright for the company based on the expected growth in sales of its PCT-based instrument systems. PBI’s revenue should be additionally impacted by the development of its newest high-pressure technology platform, ultra shear technology (UST). UST offers the potential to produce highly stable, clean and cost-effective nanoemulsions that facilitate the production of food products with enhanced shelf lives without the need for chemicals or preservatives, as detailed in a recent article (http://nnw.fm/U0P5r). The company believes that its UST technology platform can be applied across a multitude of industries seeking to satisfy consumer demand for chemical- and preservative-free food products that have longer shelf-lives, greater safety and do not require refrigeration until opened. These areas include pharmaceuticals, nutraceuticals, cosmetics, paints and industrial lubricants.
For more information, visit the company’s website at www.PressureBioSciences.com
More from NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.networknewswire.com